Key result
Captopril reduces blood pressure and cuts albuminuria ~50% in sorafenib-treated rats.
Why the study?
Does captopril reduce hypertension and renal injury in rats treated with sorafenib?
Population
Rats administered the vascular endothelial growth factor inhibitor (VEGFi) sorafenib (20 mg/kg per day)
Comparison
Captopril administered concurrently for 4 weeks vs Sorafenib alone
Design
Preclinical
Follow-up
4 weeks
Authors
Loading...
Captopril attenuates sorafenib-induced hypertension and albuminuria in rats; hypothesis-generating for cardio-oncology, human trials required.
Does captopril reduce hypertension and renal injury in rats treated with sorafenib?
Effect estimate: 30 mmHg decrease
Absolute Event Rate: 155% vs 182%
p-value: p=< 0.05
Captopril attenuates VEGFi-induced hypertension and renal injury in a preclinical model, suggesting a potential protective role in cardio-oncology.
Nagasawa et al. (2012) studied Sorafenib-induced hypertension and renal injury. Captopril vs. Sorafenib alone (20 mg/kg per day) was evaluated on Blood pressure (30 mmHg decrease, p=< 0.05). Captopril treatment in rats administered sorafenib decreased blood pressure (155 vs 182 mmHg; P<0.05) and reduced albuminuria by 50% (20 vs 42 mg/day; P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: